China’s first foreign patient treated with axicabtagene ciloleucel CAR-T therapy has been discharged from Shanghai Jiahui International Hospital. A Singaporean mother with refractory lymphoma chose Jiahui for its world-class care, shorter wait and lower cost vs Western countries. Supported by a full MDT team, she recovered smoothly, marking a milestone for China’s international CAR-T treatment.

The world’s first CAR-T therapy for solid tumors, Kailimei® (CT041), has been approved in China for advanced gastric cancer. A milestone breakthrough, it marks China’s leap from follower to leader in solid tumor cell therapy. Jiahui International Cancer Center is among the first to offer this innovative treatment, bringing new hope to patients.

Assisted reproduction is a road full of unknowns. For patients, nothing is more needed than a professional team, reliable technology, and trust between people. At the Reproductive Medicine Center of Jiahui Health, the long-term cooperation between the clinical and embryo laboratory teams led by Professor Sun Xiaoxi and Director Sun Yijuan is the source of this confidence – precise clinical decision-making, meticulous laboratory execution, mutual trust, and joint face of ever